BIOMEDIT
)
BiomEdit is an emerging animal health biotechnology company that leverages a unique platform combining the leading science of the microbiome with synthetic biology to innovate novel animal health products to address challenges in livestock production and pet health. Founded through a strategic partnership in 2022 between Elanco Animal Health (NYSE: ELAN) and Ginkgo Bioworks (NYSE: DNA), the company was born from a carve-out of technology and assets from Elanco combined with access to Ginkgo's leading cell programming platform technology. BiomEdit is a private venture funded by Anterra Capital, Viking Global Investors, Ferment, and Nutreco Ventures. In 2022, BiomEdit was recognized by S&P Global Animal Health as Best Start-up in Animal Health in its annual animal health industry awards.